Targeted chemotherapy infusion aims to control advanced stomach cancer

NCT ID NCT07655024

Recruiting now Disease control Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether delivering FOLFOX chemotherapy directly into the arteries feeding the tumor can help control advanced stomach or gastroesophageal junction cancer. The study includes 31 adults who cannot have surgery due to frailty or other health issues. The main goal is to see if this approach improves quality of life and slows disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FOLFOX chemotherapy (oxaliplatin, 5-fluorouracil, leucovorin)
What this could lead to: If successful, this approach could offer a new treatment option for people with advanced gastric cancer who cannot have surgery, potentially improving tumor control and quality of life.
What could go wrong: This is a small, early-phase trial with only 31 participants, so results may not apply broadly. The procedure carries risks like infection, bleeding, or allergic reactions, and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER (DIAGNOSIS) GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Department of General Surgery, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange St, West-city District, Beijing, China
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.